Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Brian M. Wolpin, MD, MPH


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Director, Gastrointestinal Cancer Center
  • Co-Director, Pancreas and Biliary Tumor Center
  • Physician
  • Robert T. and Judith B. Hale Chair in Pancreatic Cancer
  • Associate Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Gastrointestinal cancers

Contact Information

  • Appointments877-332-4294
  • Office Phone Number617-632-6942
  • Fax617-632-5370

Bio

Dr. Wolpin received his medical degree from Harvard Medical School in 2001. He subsequently completed his residency in Internal Medicine at Brigham and Women's Hospital, and his fellowship in Medical Oncology at the Dana-Farber Cancer Institute. He joined the staff of DFCI and Brigham and Women's Hospital in 2007, where he is a medical oncologist and clinical investigator in the Center for Gastrointestinal Oncology. His research focuses on biomarkers and novel therapeutics in gastrointestinal malignancies, and mechanisms by which lifestyle factors interact with malignant risk and progression.

Board Certification:

  • Internal Medicine
  • Medical Oncology, 2007

Fellowship:

  • Dana-Farber/Partners CancerCare, Medical Oncology

Residency:

  • Brigham and Women's Hospital, Chief Resident
  • Brigham and Women's Hospital, Internal Medicine

Medical School:

  • Harvard Medical School

Research

Unrestrained eating behavior and risk of digestive system cancers: a prospective cohort study. Am J Clin Nutr. 2021 Nov 08; 114(5):1612-1624.
View in: PubMed

Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature. 2021 Nov; 599(7884):302-307.
View in: PubMed

Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Am J Clin Nutr. 2021 10 04; 114(4):1408-1417.
View in: PubMed

A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Am J Hum Genet. 2021 10 07; 108(10):1852-1865.
View in: PubMed

Unrestrained eating behavior and risk of mortality: A prospective cohort study. Clin Nutr. 2021 Nov; 40(11):5419-5429.
View in: PubMed

Prediagnostic Inflammation and Pancreatic Cancer Survival. J Natl Cancer Inst. 2021 Sep 04; 113(9):1186-1193.
View in: PubMed

Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precis Oncol. 2021; 5.
View in: PubMed

Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. J Clin Oncol. 2021 Oct 10; 39(29):3199-3206.
View in: PubMed

Inherited Pancreatic Cancer Syndromes and High-Risk Screening. Surg Oncol Clin N Am. 2021 Oct; 30(4):773-786.
View in: PubMed

Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Clin Cancer Res. 2021 Jul 20.
View in: PubMed

Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2021 Jul 13; 36(2):109367.
View in: PubMed

Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med. 2021 06 24; 384(25):2382-2393.
View in: PubMed

Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. HGG Adv. 2021 Jul 08; 2(3).
View in: PubMed

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021 Aug 15; 27(16):4574-4586.
View in: PubMed

FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 Oct; 11(10):2488-2505.
View in: PubMed

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 04 01; 19(4):439-457.
View in: PubMed

Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discov. 2021 Aug; 11(8):2014-2031.
View in: PubMed

Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. Pancreas. 2021 03 01; 50(3):251-279.
View in: PubMed

Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Cancer Res. 2021 06 01; 81(11):3134-3143.
View in: PubMed

Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2021 04; 30(4):757-764.
View in: PubMed

A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Med. 2021 02 01; 13(1):15.
View in: PubMed

Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer. JCO Oncol Pract. 2021 02; 17(2):e236-e247.
View in: PubMed

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clin Cancer Res. 2021 03 15; 27(6):1695-1705.
View in: PubMed

Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2020 12 15; 33(11):108493.
View in: PubMed

Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Gastroenterology. 2021 03; 160(4):1373-1383.e6.
View in: PubMed

Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Early Detection. Front Oncol. 2020; 10:596931.
View in: PubMed

Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Clin Cancer Res. 2021 02 15; 27(4):1069-1081.
View in: PubMed

Population-Scale CT-based Body Composition Analysis of a Large Outpatient Population Using Deep Learning to Derive Age-, Sex-, and Race-specific Reference Curves. Radiology. 2021 02; 298(2):319-329.
View in: PubMed

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. Cancers (Basel). 2020 Nov 20; 12(11).
View in: PubMed

Bead-Based Extracellular Vesicle Analysis Using Flow Cytometry. Adv Biosyst. 2020 12; 4(12):e2000203.
View in: PubMed

Diabetes, Weight Change, and Pancreatic Cancer Risk. JAMA Oncol. 2020 10 01; 6(10):e202948.
View in: PubMed

A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. J Natl Cancer Inst. 2020 10 01; 112(10):1003-1012.
View in: PubMed

Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020 12; 29(12):2735-2739.
View in: PubMed

Prediagnostic Circulating Concentrations of Vitamin D Binding Protein and Survival among Patients with Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2020 11; 29(11):2323-2331.
View in: PubMed

Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. Nat Commun. 2020 08 27; 11(1):4296.
View in: PubMed

The Mediterranean diet, plasma metabolome, and cardiovascular disease risk. Eur Heart J. 2020 07 21; 41(28):2645-2656.
View in: PubMed

Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Cancer Res. 2020 09 15; 80(18):4004-4013.
View in: PubMed

Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nat Commun. 2020 07 03; 11(1):3353.
View in: PubMed

Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Cancer Cell. 2020 08 10; 38(2):198-211.e8.
View in: PubMed

Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiol Biomarkers Prev. 2020 09; 29(9):1784-1791.
View in: PubMed

Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies. Br J Cancer. 2020 09; 123(5):844-851.
View in: PubMed

Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2020 08; 29(8):1586-1595.
View in: PubMed

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020 06; 26(6):878-885.
View in: PubMed

Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. Cancer Epidemiol Biomarkers Prev. 2020 05; 29(5):999-1008.
View in: PubMed

Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell. 2020 05 14; 181(4):832-847.e18.
View in: PubMed

Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020 06; 16(6):635-643.
View in: PubMed

Response to the letter by Lai et al. regarding our manuscript "Statin use and pancreatic cancer risk in two prospective cohort studies". J Gastroenterol. 2020 04; 55(4):473-474.
View in: PubMed

A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. Invest New Drugs. 2020 10; 38(5):1533-1539.
View in: PubMed

Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013 Jul; 24(7):1792-1801.
View in: PubMed

Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Ann Surg Oncol. 2020 Apr; 27(4):1191-1200.
View in: PubMed

Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discov. 2020 01; 10(1):104-123.
View in: PubMed

Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev. 2019 12; 28(12):2062-2069.
View in: PubMed

Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2019 11; 28(11):1868-1875.
View in: PubMed

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2020 06; 38(3):800-811.
View in: PubMed

Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. J Natl Cancer Inst. 2019 Jun 01; 111(6):557-567.
View in: PubMed

Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. Cancer Causes Control. 2019 Jul; 30(7):757-765.
View in: PubMed

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA. 2019 04 09; 321(14):1370-1379.
View in: PubMed

Metabolic Alterations as a Signpost to Early Pancreatic Cancer. Gastroenterology. 2019 05; 156(6):1560-1563.
View in: PubMed

Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Br J Cancer. 2019 04; 120(8):848-854.
View in: PubMed

Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw. 2019 03 01; 17(3):202-210.
View in: PubMed

Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). J Natl Cancer Inst. 2019 02 01; 111(2):170-179.
View in: PubMed

Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. AJR Am J Roentgenol. 2019 03; 212(3):596-601.
View in: PubMed

iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther. 2018 11; 17(11):2377-2388.
View in: PubMed

Re: Regular use of aspirin or non-aspirin nonsteroidal anti-inflammatory drugs is not associated with risk of incident pancreatic cancer in two large cohort studies. Gastroenterology. 2018 Aug 09.
View in: PubMed

Reply. Gastroenterology. 2018 Aug 09.
View in: PubMed

Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019 01; 21(1):213-223.
View in: PubMed

Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature. 2018 06; 558(7711):600-604.
View in: PubMed

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
View in: PubMed

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 2018 09; 8(9):1112-1129.
View in: PubMed

Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol. 2018 04 25; 9(4):145.
View in: PubMed

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420.
View in: PubMed

Publisher correction: Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. Nat Commun. 2018 03 05; 9:16159.
View in: PubMed

Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2018 08; 16(8):1300-1306.e3.
View in: PubMed

Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun. 2018 02 08; 9(1):556.
View in: PubMed

Statin use and pancreatic cancer risk in two prospective cohort studies. J Gastroenterol. 2018 Aug; 53(8):959-966.
View in: PubMed

Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology. 2018 04; 154(5):1380-1390.e5.
View in: PubMed

Covariate selection for association screening in multiphenotype genetic studies. Nat Genet. 2017 Dec; 49(12):1789-1795.
View in: PubMed

Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Br J Cancer. 2017 Dec 05; 117(12):1874-1882.
View in: PubMed

Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells. Oncotarget. 2017 Oct 20; 8(50):87379-87389.
View in: PubMed

Reply to the letter to the editor 'Borderline resectable pancreatic cancer: an evolving concept' by Petrucciani et al. Ann Oncol. 2017 09 01; 28(9):2316.
View in: PubMed

Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Ann Oncol. 2017 Sep 01; 28(9):2067-2076.
View in: PubMed

Influence of dietary insulin scores on survival in colorectal cancer patients. Br J Cancer. 2017 Sep 26; 117(7):1079-1087.
View in: PubMed

Critical role for arginase 2 in obesity-associated pancreatic cancer. Nat Commun. 2017 08 14; 8(1):242.
View in: PubMed

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 08; 15(8):1028-1061.
View in: PubMed

Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017 Jul 27; 17(1):505.
View in: PubMed

Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. Gastroenterology. 2017 11; 153(5):1284-1294.e1.
View in: PubMed

Identifying the metabolomic fingerprint of high and low flavonoid consumers. J Nutr Sci. 2017; 6:e34.
View in: PubMed

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017 07 27; 547(7664):453-457.
View in: PubMed

Quantifying the Genetic Correlation between Multiple Cancer Types. Cancer Epidemiol Biomarkers Prev. 2017 09; 26(9):1427-1435.
View in: PubMed

Characterising cis-regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. Gut. 2018 03; 67(3):521-533.
View in: PubMed

Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer. Oncologist. 2017 08; 22(8):925-933.
View in: PubMed

Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. Nat Commun. 2017 05 02; 8:15034.
View in: PubMed

Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. JAMA Oncol. 2017 May 01; 3(5):636-651.
View in: PubMed

Cigarette Smoking and Pancreatic Cancer Survival. J Clin Oncol. 2017 Jun 01; 35(16):1822-1828.
View in: PubMed

Reply to A. Braillon. J Clin Oncol. 2017 04 01; 35(10):1136-1137.
View in: PubMed

Winner's Curse Correction and Variable Thresholding Improve Performance of Polygenic Risk Modeling Based on Genome-Wide Association Study Summary-Level Data. PLoS Genet. 2016 Dec; 12(12):e1006493.
View in: PubMed

When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma. J Clin Oncol. 2017 Feb 10; 35(5):485-489.
View in: PubMed

Functional characterization of a chr13q22.1 pancreatic cancer risk locus reveals long-range interaction and allele-specific effects on DIS3 expression. Hum Mol Genet. 2016 11 01; 25(21):4726-4738.
View in: PubMed

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 11; 27(11):2124-2130.
View in: PubMed

Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Cancer Res. 2016 12 15; 76(24):7160-7167.
View in: PubMed

Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer. Gut. 2017 06; 66(6):1116-1122.
View in: PubMed

Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget. 2016 Oct 11; 7(41):66328-66343.
View in: PubMed

Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science. 2016 09 09; 353(6304):1161-5.
View in: PubMed

Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report. Pancreas. 2016 09; 45(8):1080-91.
View in: PubMed

Functional characterization of a chr13q22.1 pancreatic cancer risk locus reveals long-range interaction and allele-specific effects on DIS3 expression. Hum Mol Genet. 2016 Aug 30.
View in: PubMed

Nurses' Health Study Contributions on the Epidemiology of Less Common Cancers: Endometrial, Ovarian, Pancreatic, and Hematologic. Am J Public Health. 2016 Sep; 106(9):1608-15.
View in: PubMed

Cumulative consumption of branched-chain amino acids and incidence of type 2 diabetes. Int J Epidemiol. 2016 10; 45(5):1482-1492.
View in: PubMed

Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. J Clin Oncol. 2016 08 20; 34(24):2899-905.
View in: PubMed

Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nat Commun. 2016 06 13; 7:11843.
View in: PubMed

Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiol Biomarkers Prev. 2016 07; 25(7):1185-91.
View in: PubMed

A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Invest New Drugs. 2016 06; 34(3):319-28.
View in: PubMed

Impact of Pre-analytic Blood Sample Collection Factors on Metabolomics. Cancer Epidemiol Biomarkers Prev. 2016 05; 25(5):823-829.
View in: PubMed

Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. J Natl Cancer Inst. 2016 Jun; 108(6):djv409.
View in: PubMed

Circulating Exosomes in Pancreatic Cancer: Will They Succeed on the Long, Littered Road to Early Detection Marker? Clin Chem. 2016 Feb; 62(2):307-9.
View in: PubMed

Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl Cancer Inst. 2015 Dec; 107(12):djv279.
View in: PubMed

Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. Ann Oncol. 2015 Nov; 26(11):2257-66.
View in: PubMed

Pancreatic Cancer. Hematol Oncol Clin North Am. 2015 Aug; 29(4):xiii-xiv.
View in: PubMed

Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nat Genet. 2015 Aug; 47(8):911-6.
View in: PubMed

TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Int J Cancer. 2015 Nov 01; 137(9):2175-83.
View in: PubMed

Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am. 2015 Aug; 29(4):761-76.
View in: PubMed

Reply to Y. Mao et al. J Clin Oncol. 2015 Jun 20; 33(18):2121-2.
View in: PubMed

Characterization of large structural genetic mosaicism in human autosomes. Am J Hum Genet. 2015 Mar 05; 96(3):487-97.
View in: PubMed

Correlation of CT patterns of primary intrahepatic cholangiocarcinoma at the time of presentation with the metastatic spread and clinical outcomes: retrospective study of 92 patients. Abdom Imaging. 2014 Dec; 39(6):1193-201.
View in: PubMed

Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol. 2015 Jan 01; 33(1):29-35.
View in: PubMed

Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014 10; 20(10):1193-1198.
View in: PubMed

A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs. 2015 Feb; 33(1):128-37.
View in: PubMed

Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nat Genet. 2014 Sep; 46(9):994-1000.
View in: PubMed

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014 Aug; 12(8):1083-93.
View in: PubMed

Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014 Dec 15; 23(24):6616-33.
View in: PubMed

Managing advanced colorectal cancer: have we reached the PEAK with current therapies? J Clin Oncol. 2014 Jul 20; 32(21):2200-2.
View in: PubMed

Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014 Jun; 19(6):637-8.
View in: PubMed

Variants associated with susceptibility to pancreatic cancer and melanoma do not reciprocally affect risk. Cancer Epidemiol Biomarkers Prev. 2014 Jun; 23(6):1121-4.
View in: PubMed

Nut consumption and risk of pancreatic cancer in women. Br J Cancer. 2013 Nov 26; 109(11):2911-6.
View in: PubMed

Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013 Nov 20; 31(33):4229-34.
View in: PubMed

An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS One. 2013; 8(9):e72311.
View in: PubMed

Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):e117-e123.
View in: PubMed

Reproducibility of metabolomic profiles among men and women in 2 large cohort studies. Clin Chem. 2013 Nov; 59(11):1657-67.
View in: PubMed

Hyperglycemia, insulin resistance, impaired pancreatic ß-cell function, and risk of pancreatic cancer. J Natl Cancer Inst. 2013 Jul 17; 105(14):1027-35.
View in: PubMed

Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist. 2013; 18(4):377-8.
View in: PubMed

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2014 Feb; 32(1):113-22.
View in: PubMed

Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts. Cancer Epidemiol Biomarkers Prev. 2013 May; 22(5):855-61.
View in: PubMed

A resequence analysis of genomic loci on chromosomes 1q32.1, 5p15.33, and 13q22.1 associated with pancreatic cancer risk. Pancreas. 2013 Mar; 42(2):209-15.
View in: PubMed

Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013 Jul; 24(7):1792-1801.
View in: PubMed

Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4. Cancer Causes Control. 2013 Mar; 24(3):595-602.
View in: PubMed

Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013 Apr; 26(4):465-84.
View in: PubMed

Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy. Oncologist. 2013; 18(1):64-72.
View in: PubMed

A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst. 2013 Jan 16; 105(2):95-103.
View in: PubMed

Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Gut. 2014 Jan; 63(1):152-60.
View in: PubMed

Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control. 2013 Jan; 24(1):13-25.
View in: PubMed

Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer. 2012 Oct; 19(5):615-23.
View in: PubMed

ABO blood group and risk of coronary heart disease in two prospective cohort studies. Arterioscler Thromb Vasc Biol. 2012 Sep; 32(9):2314-20.
View in: PubMed

Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012; 7(6):e38231.
View in: PubMed

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 01; 10(6):703-13.
View in: PubMed

Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012 May 06; 44(6):651-8.
View in: PubMed

Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Carcinogenesis. 2012 Jul; 33(7):1384-90.
View in: PubMed

ABO blood group and breast cancer incidence and survival. Int J Cancer. 2012 May 01; 130(9):2129-37.
View in: PubMed

Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist. 2012; 17(1):14.
View in: PubMed

Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab. Oncologist. 2012; 17(1):14-e35.
View in: PubMed

Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2012 Jan; 21(1):82-91.
View in: PubMed

A phase 2 study of oral MKC-1, an inhibitor of importin-ß, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug; 30(4):1614-20.
View in: PubMed

Dietary insulin load, dietary insulin index, and risk of pancreatic cancer. Am J Clin Nutr. 2011 Sep; 94(3):862-8.
View in: PubMed

Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. Am J Hematol. 2011 Jul; 86(7):625-7.
View in: PubMed

The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4114.
View in: PubMed

Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET). J Clin Oncol. 2011 May 20; 29(15_suppl):4120.
View in: PubMed

Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol. 2011 May 20; 29(15_suppl):4031.
View in: PubMed

Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma. Cancer Imaging. 2011 Mar 31; 11:37-41.
View in: PubMed

ABO blood group and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2011 May; 20(5):1017-20.
View in: PubMed

A single-arm trial of panitumumab in cetuximab refractory KRAS wild-type colorectal cancer. J Clin Oncol. 2011 Feb; 29(4_suppl):428.
View in: PubMed

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011 Jun; 22(6):1367-1373.
View in: PubMed

Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 2010 Dec; 19(12):3140-9.
View in: PubMed

Prospective study of ABO blood type and the risk of pulmonary embolism in two large cohort studies. Thromb Haemost. 2010 Nov; 104(5):962-71.
View in: PubMed

Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer. 2010 Sep 01; 127(6):1421-8.
View in: PubMed

Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med. 2010 May 10; 170(9):791-802.
View in: PubMed

Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. Br J Cancer. 2010 Apr 27; 102(9):1422-7.
View in: PubMed

A step forward in the treatment of advanced biliary tract cancer. N Engl J Med. 2010 Apr 08; 362(14):1335-7.
View in: PubMed

Alcohol intake and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan). Cancer Causes Control. 2010 Aug; 21(8):1213-25.
View in: PubMed

ABO blood group and incidence of epithelial ovarian cancer. Int J Cancer. 2011 Jan 15; 128(2):482-6.
View in: PubMed

Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res. 2010 Feb 01; 70(3):1015-23.
View in: PubMed

A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010 Mar; 42(3):224-8.
View in: PubMed

Clinical problem-solving. The writing on the wall. N Engl J Med. 2009 Oct 01; 361(14):1387-92.
View in: PubMed

Interactive medical case. The writing on the wall. N Engl J Med. 2009 Sep 10; 361(11):e19.
View in: PubMed

Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5931-6.
View in: PubMed

Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer. Br J Cancer. 2009 Sep 15; 101(6):916-23.
View in: PubMed

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009 Sep; 41(9):986-90.
View in: PubMed

Defining determinants of pancreatic cancer risk: are we making progress? J Natl Cancer Inst. 2009 Jul 15; 101(14):972-3.
View in: PubMed

A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. Am J Gastroenterol. 2009 Aug; 104(8):2047-56.
View in: PubMed

A cohort study of p27 localization in colon cancer, body mass index, and patient survival. Cancer Epidemiol Biomarkers Prev. 2009 Jun; 18(6):1849-58.
View in: PubMed

ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2009 Mar 18; 101(6):424-31.
View in: PubMed

Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res. 2008 Dec 15; 14(24):8263-9.
View in: PubMed

Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol. 2009 Jan 10; 27(2):176-85.
View in: PubMed

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009 Jan 10; 27(2):193-8.
View in: PubMed

Prediagnostic plasma folate and the risk of death in patients with colorectal cancer. J Clin Oncol. 2008 Jul 01; 26(19):3222-8.
View in: PubMed

Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):4614.
View in: PubMed

Systemic treatment of colorectal cancer. Gastroenterology. 2008 May; 134(5):1296-310.
View in: PubMed

Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev. 2007 Oct; 16(10):2101-9.
View in: PubMed

Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res. 2007 Aug 15; 67(16):7923-8.
View in: PubMed

Plasma folate, vitamin B6, vitamin B12, and homocysteine and pancreatic cancer risk in four large cohorts. Cancer Res. 2007 Jun 01; 67(11):5553-60.
View in: PubMed

Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer. 2007 Jul 02; 97(1):98-104.
View in: PubMed

Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007 May-Jun; 57(3):168-85.
View in: PubMed

CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007 May; 450(5):529-37.
View in: PubMed

Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Submitted. 2006.

Insulin-like growth factor binding protein-1 and the risk of pancreatic cancer in four prospective cohorts. Submitted. 2006.

CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal cancer. Submitted. 2006.

Plasma folate, vitamins B6, B12, and homocysteine and pancreatic cancer risk in four large cohorts. Submitted. 2006.

Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Submitted. 2006.

Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Sep; 6(3):208-13.
View in: PubMed

Learning to cope: how far is too close? Oncologist. 2005 Jun-Jul; 10(6):449-56.
View in: PubMed

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 2004 Sep 15; 104(6):1855-8.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top